Naureen Quibria

Stock Analyst at Capital One

(n/a)

# 4,813

Out of 4,820 analysts

9

Total ratings

9.09%

Success rate

-47.07%

Average return

Main Sectors:

Top Industries:

Stocks Rated by Naureen Quibria

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	BMEA Biomea Fusion	Initiates: Overweight	$25	$2.18	+1,049.43%	1	Aug 29, 2024
	IMMP Immutep	Initiates: Overweight	$10	$1.62	+517.28%	1	May 17, 2024
	ERAS Erasca	Initiates: Overweight	$8	$1.39	+475.54%	1	Mar 11, 2024
	CARM Carisma Therapeutics	Initiates: Overweight	$10	$0.23	+4,338.53%	1	Oct 3, 2023
	IMCR Immunocore Holdings	Initiates: Overweight	$84	$30.13	+178.79%	1	Aug 16, 2023
	DAWN Day One Biopharmaceuticals	Initiates: Overweight	$40	$7.74	+416.80%	1	Feb 8, 2023
	FENC Fennec Pharmaceuticals	Initiates: Overweight	$11	$5.69	+93.32%	1	Sep 7, 2022
	GNTA Genenta Science	Initiates: Buy	$21	$4.04	+419.80%	1	Jan 13, 2022
	KZIA Kazia Therapeutics	Initiates: Buy	$900	$3.77	+23,772.68%	1	Oct 14, 2021

Biomea Fusion

Aug 29, 2024

Initiates: Overweight

Price Target: $25

Current: $2.18

Upside: +1,049.43%

Immutep

May 17, 2024

Initiates: Overweight

Price Target: $10

Current: $1.62

Upside: +517.28%

Erasca

Mar 11, 2024

Initiates: Overweight

Price Target: $8

Current: $1.39

Upside: +475.54%

Carisma Therapeutics

Oct 3, 2023

Initiates: Overweight

Price Target: $10

Current: $0.23

Upside: +4,338.53%

Immunocore Holdings

Aug 16, 2023

Initiates: Overweight

Price Target: $84

Current: $30.13

Upside: +178.79%

Day One Biopharmaceuticals

Feb 8, 2023

Initiates: Overweight

Price Target: $40

Current: $7.74

Upside: +416.80%

Fennec Pharmaceuticals

Sep 7, 2022

Initiates: Overweight

Price Target: $11

Current: $5.69

Upside: +93.32%

Genenta Science

Jan 13, 2022

Initiates: Buy

Price Target: $21

Current: $4.04

Upside: +419.80%

Kazia Therapeutics

Oct 14, 2021

Initiates: Buy

Price Target: $900

Current: $3.77

Upside: +23,772.68%